Skip to content
type1.science
Phase 2Completed

USTEKID: Ustekinumab in adolescents with recent-onset type 1 diabetes

Multicenter double-blind randomized phase-2 trial of ustekinumab in adolescents with recent-onset T1D. It met its 12-month C-peptide endpoint with no increase in adverse events.

Primary endpoints

  • Stimulated C-peptide at 12 months

Results so far

Stimulated C-peptide was 49% higher in the ustekinumab group at 12 months (P=0.02), with no increase in adverse events.

The full picture

USTEKID is the published adolescent signal that made ustekinumab worth tracking: positive 12-month C-peptide preservation, tolerability that looks acceptable, and a plausible Th17.1-linked mechanism.